



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Bersanlimab

Cat. No.:	HY-P99473
CAS No.:	1987854-08-9
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects ^[1] .								
In Vitro	BI-505 (1 ng/mL-1000 µg/mL) dose-dependently induces programmed cell death (PCD) in ICAM-1-expressing Ramos, Raji, and Daudi lymphoma cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Bersanlimab (BI-505; 20 mg/kg; i.p.; twice-weekly; for 21 days) significantly reduces tumor growth and prolongs animal survival ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>SCID mice injected with ARH-77 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; twice-weekly; for 21 days</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced tumor growth and prolonged animal survival.</td> </tr> </table>	Animal Model:	SCID mice injected with ARH-77 cells ^[1]	Dosage:	20 mg/kg	Administration:	i.p.; twice-weekly; for 21 days	Result:	Significantly reduced tumor growth and prolonged animal survival.
Animal Model:	SCID mice injected with ARH-77 cells ^[1]								
Dosage:	20 mg/kg								
Administration:	i.p.; twice-weekly; for 21 days								
Result:	Significantly reduced tumor growth and prolonged animal survival.								

REFERENCES

[1]. Niina Veitonmäki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. *Cancer Cell*. 2013 Apr 15;23(4):502-15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA